About Dr. Natalia Sutiman
Dr. Natalia Sutiman
MD (Duke-NUS)
Special interests:
Preventive Medicine
Dr Natalia Sutiman is a medical doctor dedicated to providing evidence-driven and
patient-centred care. She earned her Doctor of Medicine (MD) degree from Duke-NUS Medical
School and is currently completing her Graduate Diploma in Family Medicine (GDFM).
Her medical training includes rotations in Internal Medicine, Emergency Medicine and
Orthopaedic Surgery at Singapore General Hospital, Paediatric Medicine and Children's
Emergency at KK Women's and Children's Hospital, and primary care at SingHealth Polyclinics.
This broad clinical training allows her to care for patients across all ages and a wide
range of acute and chronic conditions.
Before pursuing medicine, Dr Natalia worked as a pharmacist at Tan Tock Seng Hospital and later in
Clinical Pharmacology with SingHealth. During this time, she was involved in clinical trials,
therapeutic drug monitoring and genomics research. These experiences continue to shape her careful,
science-based approach to diagnosis and patient care.
Dr Natalia is also a published researcher with more than 400 citations in peer-reviewed journals.
Her work focuses on pharmacogenomics, which studies how genetic differences influence how
individuals respond to medications. Her research has examined how genetic variants affect drug
metabolism and treatment outcomes in Asian patient populations across conditions including cancer
and inflammatory diseases.
While her career includes extensive research and academic work, Dr Natalia has always been drawn to
the human side of medicine. She values building meaningful relationships with her patients,
listening carefully to their concerns, and guiding them through medical decisions with clarity and
empathy.
She has particular interests in preventive medicine and longevity, and enjoys working
collaboratively with patients to make informed choices that support their long-term health. She also
finds fulfilment in assessing evolving or complex symptoms and helping patients navigate diagnostic
uncertainty in primary care.
Outside of medicine, Dr Natalia enjoys hiking and has a personal appreciation for the health
considerations involved in travel and high altitude
adventures. She also enjoys running, yoga, meditation and mindfulness practices, and
spending time with her loved ones.
Publications
-
Identifying the thresholds of C-reactive protein, procalcitonin, and interleukin-6 among children ≤ 36 months' old with fever without source at risk of serious bacterial infections: A systematic review and meta-analysisSutiman, N., Lin, J., Sultana, R., Yao, S. H. W., Goh, S. S. M., Rocknathan, S.-K., Ganapathy, S., & Chong, S.-L. (2026). Frontiers in Pediatrics, 14, 1697210. doi.org/10.3389/fped.2026.1697210
-
Asthma exacerbation in children—Is there pneumonia?Kotturu, V., Ganapathy, S., & Sutiman, N. (2025). Acta Paediatrica, 114, 563.
-
Protocol for the diagnostic performance of C reactive protein, procalcitonin and interleukin-6 for serious bacterial infections among children ≤ 36 months old presenting with fever without source: A systematic review and meta-analysisSutiman, N., Yao, S. H. W., Goh, S. S. M., Sultana, R., & Chong, S.-L. (2024). BMJ Paediatrics Open, 8(1), e002237. doi.org/10.1136/bmjpo-2023-002237
-
Delayed presentation is associated with serious bacterial infections among febrile infants: A prospective cohort studyRajoo, K. P., Sutiman, N., Shih, S., Khoo, Z. X., Ong, G. Y.-K., Wong, L., Piragasam, R., Ganapathy, S., & Chong, S.-L. (2024). Annals of the Academy of Medicine, Singapore, 53(5), 286–292. doi.org/10.47102/annals-acadmedsg.2023350
-
Cross-ancestry genome-wide association study defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrationsKhor, C. C., Winter, S., Sutiman, N., Mürdter, T. E., Chen, S., Lim, J. S. L., et al. (2023). Clinical Pharmacology & Therapeutics, 113(3), 712–723. doi.org/10.1002/cpt.2846
-
Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13Ang, H. X., Sutiman, N., Deng, X. L., Liu, A., Cerda-Smith, C. G., et al. (2023). Proceedings of the National Academy of Sciences, 120(38), e2221448120. doi.org/10.1073/pnas.2221448120
-
Validation and comparison of the PECARN rule, Step-by-Step approach and Lab-score for predicting serious and invasive bacterial infections in young febrile infantsSutiman, N., Khoo, Z. X., Ong, G. Y.-K., Piragasam, R., & Chong, S.-L. (2022). Annals of the Academy of Medicine, Singapore, 51(10), 595–604. doi.org/10.47102/annals-acadmedsg.2022193
-
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effectsNg, M., Chen, S., Ong, W. S., Balachander, A., Seet, A., Yeong, J., Sutiman, N., et al. (2022). International Journal of Cancer, 151(3), 435–449. doi.org/10.1002/ijc.34021
-
Excellent survival outcomes of pediatric patients with acute myeloid leukemia treated with the MASPORE 2006 protocolSutiman, N., Nwe, M. S., Lai, E. E. N., Lee, D. K., Chan, M. Y., Yeoh, A. E.-J., Soh, S. Y., Leung, W., & Tan, A. M. (2021). Clinical Lymphoma Myeloma and Leukemia, 21(3), e290–e300. doi.org/10.1016/j.clml.2020.11.016
-
Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12Ang, H. X., Sutiman, N., Deng, X. L., Bartelt, L. C., Chen, Q., et al. (2021). BioRxiv, 2021.03.03.433762. doi.org/10.1101/2021.03.03.433762
-
Protocol for the diagnostic performance of C-reactive protein, procalcitonin and interleukin-6 for serious bacterial infections among children ≤ 36 months old presenting with fever without sourceSutiman, N., Yao, S. H. W., Goh, S. S. M., Sultana, R., & Chong, S. L. (2021). Health, 8.
-
Alterations in drug pharmacokinetics in critically ill children supported on extracorporeal membrane oxygenation: A systematic reviewSutiman, N., Watt, K., Hornik, C., Koh, J. C., Murphy, B., Chan, Y. H., & Lee, J. H. (2020). Australian Critical Care, 33, S2–S3. doi.org/10.1016/j.aucc.2020.04.006
-
An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patientsChen, S., Tan, W. Z., Sutiman, N., Lim, C., Lee, S. S., Leong, W. F., et al. (2020). The Pharmacogenomics Journal, 20(3), 505–515. doi.org/10.1038/s41397-019-0126-9
-
Pharmacokinetics alterations in critically ill pediatric patients on extracorporeal membrane oxygenation: A systematic reviewSutiman, N., Koh, J. C., Watt, K., Hornik, C., Murphy, B., Chan, Y. H., & Lee, J. H. (2020). Frontiers in Pediatrics, 8, 260. doi.org/10.3389/fped.2020.00260
-
Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patientsSutiman, N., Chen, S., Ling, K. L., Chuah, S. W., Leong, W. F., et al. (2018). Pharmacogenomics, 19(1), 31–43. doi.org/10.2217/pgs-2017-0147
-
EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC patientsSutiman, N., Tan, S. W., Tan, E. H., Lim, W. T., Kanesvaran, R., et al. (2017). Journal of Thoracic Oncology, 12(3), 529–538. doi.org/10.1016/j.jtho.2016.11.2225
-
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patientsMarvalim, C., Wong, J. X. G., Sutiman, N., Lim, W. T., Kanesvaran, R., et al. (2017). Pharmacogenetics and Genomics, 27(3), 120–123. doi.org/10.1097/fpc.0000000000000266
-
Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patientsLal, S., Sutiman, N., Ooi, L. L., Wong, Z. W., Wong, N. S., Ang, P. C. S., & Chowbay, B. (2017). The Pharmacogenomics Journal, 17(4), 337–343. doi.org/10.1038/tpj.2016.17
-
A phase I pharmacokinetic study of metronomic vinorelbine and sorafenib using two schedules in Asian non-small cell lung cancer (NSCLC) patientsChen, S., Sutiman, N., Shih, V., Tan, D., Ang, M. K., et al. (2017). Annals of Oncology, 28, x39–x40. doi.org/10.1093/annonc/mdx658.003
-
Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel diseaseChuah, S. N. W., Delord, P., Sutiman, N., Leong, W. F., Kong, S. C., et al. (2016). Journal of Crohn's & Colitis, 10, S307–S308. doi.org/10.1093/ecco-jcc/jjw019.534
-
Phase I study of oral vinorelbine in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) using two different schedulesSutiman, N., Zhang, Z., Tan, E. H., Ang, M. K., Tan, S.-W. D., et al. (2016). PLoS One, 11(5), e0154316. doi.org/10.1371/journal.pone.0154316
-
Effects of oxaliplatin, capecitabine and irinotecan (OXIRI) on pancreatic ductal adenocarcinoma cell lines carrying different Kras mutational statusChowbay, B., Wong, J. X. G., Marvalim, C., Ng, S. L., Sutiman, N., & Leong, W. F. (2016). Journal of Clinical Oncology, 34(15_suppl), e15722–e15722. doi.org/10.1200/jco.2016.34.15_suppl.e15722
-
Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patientsLim, J. S. L., Sutiman, N., Muerdter, T. E., Singh, O., Cheung, Y. B., et al. (2016). British Journal of Clinical Pharmacology, 81(6), 1142–1152. doi.org/10.1111/bcp.12886
-
Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patientsChen, S., Sutiman, N., & Chowbay, B. (2016). Pharmacogenomics, 17(17), 1941–1955. doi.org/10.2217/pgs-2016-0124
-
Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and their influence on tamoxifen disposition in Asian breast cancer patientsSutiman, N., Lim, J. S. L., Muerdter, T. E., Singh, O., Cheung, Y. B., et al. (2016). Clinical Pharmacokinetics, 55(10), 1239–1250. doi.org/10.1007/s40262-016-0402-7
-
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: A comparative reviewChen, S., Sutiman, N., Zhang, C. Z., Yu, Y., Lam, S., Khor, C. C., & Chowbay, B. (2016). Drug Metabolism Reviews, 48(4), 502–540. doi.org/10.1080/03602532.2016.1226896
-
Evaluation of severe neutropenia and diarrhea in Asian cancer patients receiving UGT1A1 genotype-guided irinotecan dosingSutiman, N., Ramasamy, S., Ng, C. H. M., Choo, S. P., Lim, R. W., et al. (2015). Journal of Clinical Oncology, 33(15_suppl), e13572–e13572. doi.org/10.1200/jco.2015.33.15_suppl.e13572
-
Influence of EGFR exon 19 mutation subtypes on survival outcomes in advanced stage Asian non-small cell lung cancer patients receiving TKI therapyChowbay, B., Singh, O., Sutiman, N., Tan, D. S. W., Lim, W. T., & Tan, E. H. (2014). European Journal of Cancer, 50, 32. doi.org/10.1016/s0959-8049(14)70212-6
-
Pharmacogenetics and its relevance to clinical practiceSutiman, N., & Chowbay, B. (2013). Annals of the Academy of Medicine, Singapore, 42(9), 429–431. doi.org/10.47102/annals-acadmedsg.v42n9p429